Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men

Journal of Clinical Biochemistry and Nutrition

Volumn 54, Issue 3, 2014, Pages 174-180

  Parlesak, Alexandr ^a   Eckoldt, Joachim ^b   Winkler, Karl ^c   Bode, Christian J ^d   Schaf̈er, Christian ^d  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF HOHENHEIM   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Atherogenic shift; Body mass index; Lipoprotein subfractions; Nutrition; Small dense lipoprotein particles

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MONOUNSATURATED FATTY ACID; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; HUMAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MALE; NUTRITION; PHOSPHOLIPID BLOOD LEVEL; PHYSICAL ACTIVITY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84900431355     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-78     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. (Pubitemid 36712275)
3. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
4. Olofsson SO, Borèn J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258: 395-410. (Pubitemid 41546555)
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
6. Cooney MT, Dudina A, De Bacquer D. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009; 206: 611-616.
7. März W, Scharnagl H, Winkler K, et al. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2004; 110: 3068-3074. (Pubitemid 39492000)
8. Schäfer C, Parlesak A, Eckoldt J, et al. Beyond HDL-cholesterol increase: phospholipid enrichment and shift from HDL3 to HDL2 in alcohol consumers. J Lipid Res 2007; 48: 1550-1558. (Pubitemid 47312016)
9. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008; 10: 271-278. (Pubitemid 351386024)
10. Kelley GA, Kelley KS, Roberts S, Haskell W. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr 2012; 31: 156-167.
11. Brinton EA. Effects of ethanol intake on lipoproteins. Curr Atheroscler Rep 2012; 14: 108-114.
12. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-559. (Pubitemid 40315677)
13. Williams PT, Superko HR, Haskell WL, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003; 23: 314-321. (Pubitemid 36231946)
14. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365. (Pubitemid 39359478)
15. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506. (Pubitemid 20257828)
16. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
17. Landig J, Erhardt JG, Bode JC, Bode C. Validation and comparison of two computerized methods of obtaining a diet history. Clin Nutr 1998; 17: 113-117. (Pubitemid 28349831)
18. Schofield WN, Schofield C, James WPT. Basal metabolic rate: review and prediction. Hum Nutr Clin Nutr 1985; 39(Suppl 1): 1-96.
19. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
20. Winkler K, Wetzka B, Hoffmann MM, et al. Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J Clin Endocrinol Metab 2003; 88: 1162-1166. (Pubitemid 36337771)
21. Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003; 19: 295-296. (Pubitemid 36181920)
22. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-29. (Pubitemid 43958484)
23. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302-1309.
24. Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol 2008; 101: 48B-57B.
25. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010; 45: 907-914.
26. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792-802.
27. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B. (Pubitemid 28113939)
28. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102: 1886-1892.
29. Holme I, Høstmark AT, Anderssen SA. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study. J Intern Med 2007; 262: 235-243. (Pubitemid 47087625)
30. Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1996; 16: 1509-1515. (Pubitemid 26427605)
31. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007; 167: 999-1008. (Pubitemid 46835787)
32. Jebb SA, Lovegrove JA, Griffin BA, et al. Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 2010; 92: 748-758.
33. Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids 2011; 46: 209-228.
34. Gill JM, Brown JC, Caslake MJ, et al. Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am J Clin Nutr 2003; 78: 47-56. (Pubitemid 39655247)
35. Gaziano JM, Gaziano TA, Glynn RJ, et al. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. J Am Coll Cardiol 2000; 35: 96-105. (Pubitemid 30061266)
36. Rimm EB, Moats C. Alcohol and coronary heart disease: drinking patterns and mediators of effect. Ann Epidemiol 2007; 17: S3-S7. (Pubitemid 46671513)
37. Klatsky AL. Alcohol and cardiovascular mortality. J Am Coll Cardiol 2010; 55: 1336-1338.
38. Geohas J, Daly A, Juturu V, Finch M, Komorowski JR. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci 2007; 333: 145-153. (Pubitemid 47181613)
39. Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013; 24: 301-308.
40. Brown SA, McGue M, Maggs J, et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics 2008; 121(Suppl 4): S290-S310.